Clinical trials: Pneumonia - Bacterial
- Condition Pneumonia - Bacterial
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either…
- Trial name
- NCT00370396
- Testing
- Synflorix, Prevenar, Infanrix hexa
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia
- Trial name
- LEAP2 (NCT02813694)
- Testing
- lefamulin, Moxifloxacin
- Where
- 155 sites in United States, Argentina and 18 more
- Volunteers
- 738 people
- Sponsor
- Nabriva Therapeutics AG
Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia
- Trial name
- NCT01808092
- Testing
- ceftazidim-avibactam (CAZ-AVI, experimental product), meropenem (active comparator)
- Where
- 123 sites in Argentina, Brazil and 24 more
- Volunteers
- 969 people
- Sponsor
- Pfizer
Pneumonia, Bacterial
Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia
This study will compare the safety and efficacy of a tigecycline regimen versus an imipenem/cilastatin regimen for the treatment of subjects who are hospitalized with hospital-acquired pneumonia (HAP).
- Trial name
- NCT00707239
- Testing
- tigecycline, imipenem/cilastatin
- Where
- 40 sites in United States, Argentina and 12 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Pneumonia, Bacterial, Pneumococcal Infections
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different…
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Trial name
- NCT05412030
- Testing
- AFX3772, Prevnar 13, Prevnar 20
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
The purpose of this study is to assess the safety and tolerability of doripenem compared to imipenem in Ventilator-assisted pneumonia and complicated Intra-abdominal Infection.
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Abdominal Abscess
- Trial name
- NCT00515034
- Testing
- Imipenem/cilastatin, Doripenem
- Volunteers
- 146 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pneumonia, Bacterial
Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia
To demonstrate the safety and efficacy of adjunctive therapy with the Amikacin fosfomycin inhalation system (AFIS) versus aerosolized placebo to treat Gram-negative pneumonia in mechanically ventilated patients receiving IV…
- Trial name
- IASIS (NCT01969799)
- Testing
- Amikacin fosfomycin inhalation solution
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 143 people
- Sponsor
- Cardeas Pharma
Community Acquired Bacterial Pneumonia
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- DEFINE-CABP (NCT02679573)
- Testing
- Delafloxacin, Moxifloxacin, Linezolid
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 860 people
- Sponsor
- Melinta Therapeutics, Inc.
Pneumonia, Bacterial
Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
The primary objective of this study was to evaluate the clinical efficacy of treatment with Nemonoxacin compared with Tavanic® in patients with community-acquired pneumonia (CAP).
- Trial name
- NCT03551210
- Testing
- Nemonoxacin, Tavanic
- Where
- 25 sites in Russia
- Volunteers
- 342 people
- Sponsor
- R-Pharm
Pneumococcal Infections
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)
This study will evaluate whether the aluminum-adjuvanted or the non-adjuvanted formulation of the candidate pneumococcal vaccine (V114) is non-inferior to Prevnar 13® based on immune responses to the 13 serotypes in common…
- Trial name
- NCT01215188
- Testing
- V114 Aluminum-adjuvanted, V114 Non-adjuvanted, Prevnar 13®
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
HIV, Pneumonia
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus.
- Conditions
- HIV, Pneumonia, Infections, Pneumococcal
- Trial name
- NCT05794191
- Testing
- Vaccine Administration
- Where
- United States
- Volunteers
- 350,399 people
- Sponsor
- Pfizer
Bacterial Pneumonia, Community-Acquired Infections
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT02531438
- Testing
- Omadacycline, Moxifloxacin
- Where
- 140 sites in United States, Belgium and 23 more
- Volunteers
- 774 people
- Sponsor
- Paratek Pharmaceuticals Inc
Community-acquired Bacterial Pneumonia
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).
- Trial name
- NCT02605122
- Testing
- Solithromycin, Standard of Care
- Where
- 58 sites in United States, Bulgaria and 4 more
- Volunteers
- 97 people
- Sponsor
- Melinta Therapeutics, Inc.
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bacterial Pneumonia
Cx611-0204 SEPCELL Study
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in…
- Trial name
- SEPCELL (NCT03158727)
- Testing
- Cx611
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 84 people
- Sponsor
- Tigenix S.A.U.
Community-acquired Pneumonia, Bacterial Pneumonia
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT04779242
- Testing
- Omadacycline, Moxifloxacin
- Where
- 55 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 670 people
- Sponsor
- Paratek Pharmaceuticals Inc
Nosocomial Infections, Pneumonia, Ventilator-Associated
A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization
The study is a first step in establishing the safety and efficacy of the CytaCoat technology when applied to a medical device such as a nasal prong and the clinical data generated will serve as a basis for continuous studies in…
- Trial name
- NCT02756351
- Testing
- CytaCoat Nasal Prong, Inspiration Healthcare Inspire nCPAP Nasal Prong
- Where
- Sweden
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- CytaCoat AB
Infections
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant…
- Trial name
- NCT01645735
- Testing
- Ceftaroline fosamil, Ceftriaxone plus vancomycin
- Where
- 31 sites in United States, Georgia and 6 more
- Volunteers
- 49 people
- Sponsor
- Forest Laboratories